Vijaya Diagnostic Centre’s Board of Directors approved the Unaudited Financial Results for the third quarter ending December 31, 2025. Crucially, the board also approved several high-level executive appointments, including Mr. Ankit Shah as the new Chief Financial Officer (CFO), effective February 13, 2026. The resignation of the previous CFO was noted, and the company also sanctioned the grant of 1,15,000 ESOPs to eligible employees.
Outcome of the Board Meeting: February 13, 2026
The Board of Directors of Vijaya Diagnostic Centre Limited convened on Friday, February 13, 2026, to consider and approve several key corporate actions and results. The meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).
Financial Results Noted
The Board formally considered and noted the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2025.
Key Management Appointments Approved
Following recommendations from the Nomination and Remuneration Committee, the Board approved the following appointments, all effective from February 13, 2026:
- The appointment of Mr. Ankit Shah as Chief Financial Officer (CFO) & Key Managerial Personal. He is a Chartered Accountant with extensive experience in healthcare finance, strategy, and corporate governance.
- The appointment of Mr. Sai Siva Prasad as Chief Technology Officer (CTO). Mr. Prasad is a seasoned technology leader with experience in driving large-scale digital transformation.
- The appointment of Mr. Venkata Siva Rama Raju Vegesna as Chief Operating Officer (COO). Mr. Vegesna is a Chartered Financial Analyst (CFA) and brings significant operational strategy experience.
Additionally, two new Non-Executive-Independent Directors were appointed for a term of five (5) years, subject to shareholder approval: Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola.
CFO Resignation and Transition
The Board noted the resignation of Mr. S. Ramachandra Reddy from the position of Chief Financial Officer (CFO), effective February 13, 2026. This change is due to organizational restructuring. Mr. Reddy will continue to serve the Company in his existing role as General Manager – Finance & Accounts to ensure a smooth transition.
Employee Stock Option Plan (ESOP) Grant
The Board sanctioned the grant of 1,15,000 Employee Stock Options (ESOPs) under the “VDCL Employee Stock Option Plan 2018”. These options are convertible into 1,15,000 equity shares with a face value of ₹1/- each. The options are being granted at an Exercise Price of ₹809/- per option, which includes a 20% discount on the average closing price preceding the grant month.
Key ESOP Terms (Scheme 5)
The grant falls under Scheme 5, which focuses on Time-based options for employees in Support functions (Finance & Accounts, IT, Strategy, Operations, etc.). The vesting schedule is set as:
- 1st Year: 25%
- 2nd Year: 25%
- 3rd Year: 50%
The minimum vesting period is One (1) Year from the grant date, and the overall Exercise Period is Ten (10) years from the grant date.
Policy Revision
The Board also approved a revised Policy for Consideration and Approval of Related Party Transaction(s) (RPT Policy), based on recommendations from the Audit Committee.
Source: BSE
